Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes

Journal of Immunology

Volumn 169, Issue 6, 2002, Pages 2988-2996

  Lev, Avital ^a   Novak, Hila ^a   Segal, Dina ^a   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT ANTIBODY;

ARTICLE; CELL ACTIVITY; CELL KILLING; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; MELANOMA; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING;

EID: 0037105621     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.6.2988     Document Type: Article

References (49)

1. How tumors escape immune destruction and what we can do about it
2. Antigen-processing machinery breakdown and tumor growth
3. MHC antigens and tumor escape from immune surveillance
4. How much longer will turnout cells fool the immune system?
5. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
6. Progress in human tumour immunology and immunotherapy
7. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
8. Cytokines and immune response in the tumor microenvironment
9. Design and evaluation of antigen-specific vaccination strategies against cancer
10. The use of dendritic cells for cancer vaccination
11. T-cell-directed cancer vaccines: The melanoma model
12. Human tumor antigens recognized by T lymphocytes
13. A listing of human tumor antigens recognized by T cells
14. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
15. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
16. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy
17. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient
18. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy
19. TAP off-tumors on
20. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions
21. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines
22. Recombinant antibodies for cancer diagnosis and therapy
23. Recent advances in immunotherapy and monoclonal antibody treatment of cancer
24. Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens
25. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
26. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
27. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
28. Improved induction of melanomareactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
29. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma
30. Cytotoxic and anti-tumor activity of a recombinant immunotoxin composed of disulfide-stabilized antiTac Fy fragment and truncated Pseudomonas exotoxin
31. Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fy fragments
32. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice
33. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR
34. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes
35. + cells
36. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment
37. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines
38. Targeted therapy of cancer with recombinant immunotoxins
39. Targeted cytokines for cancer immunotherapy
40. Bi-specific antibody therapy for the treatment of cancer
41. Transport of molecules, particles, and cells in solid tumors
42. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes
43. From TCR engagement to T cell activation: A kinetic view of T cell behaviour
44. The immunological synapse
45. + T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells
46. + memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression
47. + lymphocytes using class I peptide tetramers
48. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic
49. Soluble class I MHC with β2-microglobulin covalently linked peptides: Specific binding to a T cell hybridoma